Description: Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Home Page: www.geron.com
GERN Technical Analysis
919 East Hillsdale Boulevard
Foster City,
CA
94404
United States
Phone:
650 473 7700
Officers
| Name | Title |
|---|---|
| Dr. John A. Scarlett M.D. | Chairman, Pres & CEO |
| Ms. Olivia Kyusuk Bloom | Exec. VP of Fin., CFO & Treasurer |
| Dr. Andrew J. Grethlein | Exec. VP & COO |
| Ms. Melissa A. Kelly Behrs | Exec. VP of Bus. Operations & Chief Alliance Officer |
| Mr. Anil Kapur | Exec. VP of Corp. Strategy & Chief Commercial Officer |
| Ms. Aron Feingold | VP of Investor Relations & Corp. Communications |
| Mr. Stephen N. Rosenfield J.D. | Exec. VP, Chief Legal Officer & Corp. Sec. |
| Ms. Shannon Odam | VP of HR |
| Mr. Edward E. Koval | Exec. VP & Chief Bus. Officer |
| Dr. Faye Feller M.D. | Exec. VP & Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.2822 |
| Price-to-Sales TTM: | 571.9769 |
| IPO Date: | 1996-06-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 98 |